NUVL - Nuvalent, Inc.
About Nuvalent, Inc. (https://www.nuvalent.com)
Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selective ROS1 inhibitor capable of penetrating the brain. This compound is specifically designed to target ROS1 fusions that possess the normal ROS1 kinase domain, and crucially, it retains activity against mutations known to confer resistance to both approved and experimental ROS1 inhibitors. NVL-520 is currently undergoing Phase I clinical evaluation. Nuvalent's second key asset is NVL-655, an ALK-selective inhibitor that also exhibits brain-penetrant properties. This therapy seeks to address significant limitations of earlier generations of ALK inhibitors (first-, second-, and third-generation), including the development of treatment resistance, central nervous system-related adverse effects, and brain metastases. NVL-655 is presently being assessed in Phase I/II clinical trials. The company was established in 2017 and is based in Cambridge, Massachusetts.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| James R. Porter | Chief Executive Officer, President & Director | 1976 | $1,143,133 USD |
| Christopher D. Turner | Chief Medical Officer | 1969 | $822,475 USD |
| Alex Balcom | Chief Financial Officer & Treasurer | 1984 | $753,791 USD |
| Darlene Noci | Chief Development Officer | 1978 | $741,317 USD |
| Deborah Ann Miller | Chief Legal Officer & Secretary | 1976 | $740,701 USD |
| Benjamin Lane | Chief Technical Operations Officer | – | – |
| Chelcie Lister | Senior Director of Investor Relations & Corporate Communications | – | – |
| Henry Pelish | Chief Scientific Officer | 1973 | – |
| John Soglia | Senior Vice President of Translational Development | – | – |
| Joshua Horan | Senior Vice President of Chemistry | – | – |
| Matthew Metivier | Senior Vice President of Human Resources | – | – |
| Ruth Adams | Senior Vice President of Clinical Operations | – | – |